Please check your internet connection and try again.
# Isoxsuprine Hydrochloride
## Overview
Isoxsuprine hydrochloride is a peripheral vasodilator. Its exact mechanism of action is not fully understood but is thought to involve direct relaxation of vascular smooth muscle, leading to vasodilation. It also has some beta-adrenergic agonist activity.
## Primary Indications
* Peripheral vascular disease (e.g., intermittent claudication, Buerger's disease)
* Cerebrovascular insufficiency
*Note: The efficacy of isoxsuprine for these indications is not definitively established and it is not approved by the FDA for any indication. Use may be based on local protocols or off-label practice.*
## Adult Dosing
* **Intermittent Claudication/Peripheral Vascular Disease:** 10-20 mg orally 3-4 times daily.
* **Cerebrovascular Insufficiency:** 10-20 mg orally 3-4 times daily.
* **Maximum Dose:** Generally not to exceed 80 mg per day.
Dose titration should be based on patient response and tolerance.
## Pediatric Dosing
There is no established pediatric dosing for isoxsuprine hydrochloride.
## Dose Adjustments
No specific dose adjustments are routinely recommended for renal or hepatic impairment. However, caution and close monitoring may be warranted in these populations due to potential for altered metabolism and excretion.
## Contraindications
* Hypersensitivity to isoxsuprine hydrochloride.
* Use in patients with congenital heart disease.
* Use in patients where vasodilation is undesirable (e.g., following recent hemorrhage, hypotension, tachycardia).
## Adverse Effects
* **Common:** Nausea, vomiting, gastric distress, dizziness, weakness, nervousness, rash, flushing.
* **Less Common:** Hypotension, tachycardia, palpitation, epigastric distress, drowsiness, confusion.
* **Rare:** Bleeding (especially if co-administered with anticoagulants).
## Key Drug Interactions
* **Antihypertensives:** May potentiate hypotensive effects.
* **Anticoagulants (e.g., warfarin):** May increase the risk of bleeding.
* **Sympathomimetic agents:** Potential for additive cardiovascular effects (e.g., increased heart rate, blood pressure).
## Monitoring
* Blood pressure and heart rate.
* Signs and symptoms of peripheral vascular disease (e.g., pain, color, temperature of extremities).
* Signs of bleeding, especially with concomitant anticoagulant therapy.
* Gastrointestinal tolerance.
## Clinical Pearls
* Isoxsuprine's efficacy in improving symptoms of peripheral vascular disease is debated and often considered modest.
* Oral administration is typical.
* Therapeutic benefit may take several weeks to become apparent.
* Patients should be advised to report any adverse effects, especially dizziness, hypotension, or signs of bleeding.
***
*Disclaimer: This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant guidelines before making clinical decisions. Drug information can change, and this summary may not reflect the latest updates or all possible scenarios.*
